natgillin/translations-raw huggingface dataset:
The method of claim 1, wherein the sample is from a subject prescribed an immunomodulator, a subject considering taking an immunomodulator, or a subject suspected of having Progressive Multifocal Leukoencephalopathy (PML), wherein the immunomodulator is selected from an anti-VLA-4 therapy, and anti-CD2-therapy, an anti-CD11a therapy, or mycophenolate mofetil. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je uzorak iz subjekta kojem je prepisan imunomodulator, se smatra da subjekt treba uzeti imunomodulator, ili se sumnja da subjekt ima progresivnu multifokalnu leukoencefalopatiju (PML), gdje se imunomodulator bira između terapije protiv VLA-4, terapije protiv CD2, terapije protiv CDI 1a, ili mikofenolat mofetila.
The method according to claim 8, wherein said depressive disorder is treatment resistant depression. 
Pripravak za uporabu sukladno patentnom zahtjevu 10, naznačeno time, da je navedeni depresivni poremećaj klinička depresija.
In certain embodiments, an antibody is provided that binds an isoform c-specific region of the extracellular domain of FcRH5c from, within, or overlapping amino acids 754-835 of SEQ ID NO:1. 
Izolirano protutijelo anti-FcRH5, naznačeno time, da veže izoformno c-specifično područje izvanstanične domene od FcRH5Se, prikazano kao aminokiseline 743-850 od SEQ ID NO: 1, pri čemu protutijelo ne veže značajno niti jednu drugu domenu od FcRH5, koja je nalik na Ig.
The portable cooking and delivery system of claim 1 wherein at least one of the ovens includes an ejector moveable between a retracted configuration and an expanded configuration, wherein the ejector is selectively positionable based on a dimension of the contents of the oven to bias the contents of the oven against movement during transit of the vehicle. The portable cooking and delivery system of claim 1 wherein the oven rack has oven securement structures that removably releasably secure the ovens in the oven rack. 
Postupak prema zahtjevu 9, naznačen time, da najmanje jedan od štednjaka (210) obuhvaća uređaj za izbacivanje (246) koji je pomičan između uvučene konfiguracije 1 rastegnute konfiguracije, te time, da nadalje obuhvaća sljedeće: pozicioniranje uređaja za izbacivanje na temelju dimenzija sadržina iz štednjaka, u svrhu uravnoteženja sadržaja u štednjaku, za sprečavanje njegovog pomicanja za vrijeme putovanja vozila (240).
The so obtained ink was applied in the form of a patch onto standard security paper (100 g/m2) and the imprinted paper was further processed as described in example 1. FIG. 
Tinta dobivena na takav način se nanosi u obliku otisnute površine na standardni sigurnosni papir (100 g/m'), a otisnuti papir sc dodatno obrađuje na način opisan u primjeru 1.
The expanded polystyrene molded article comprising expanded particles according to claim 13, wherein each skin layer further comprises a functional additive selected from the group consisting of expanding agents, nucleating agents, lubricants, antioxidants, thermal stabilizers, UV stabilizers, biostabilizers, fillers, reinforcing agents, plasticizers, coloring agents, impact resistance agents, flame retardants, anti-static agents, cross-linking agents, fluorescent whitening agents, thermally conducting agents, electrically conducting agents, permeation controllers, magnetic agents, surfactants, stabilizers, excipients, medicines, solvents, hardeners, moisture absorbents, reinforcing agents, flavoring agents, antimicrobial agents and mixtures thereof. 
Artikl oblikovan od ekspandiranog polistirena koji sadrži ekspandirane čestice u skladu s patentnim zahtjevom 13, naznačen time što svaki površinski sloj dodatno sadrži funkcionalni aditiv koji se bira 1z skupine koju čine sredstva za ekspandiranje, nukleacijska sredstva, maziva, antioksidansi, toplinski stabilizatori, UV stabilizatori, biostabilizatori, punila, sredstva za ojačavanje, plastifikatori, boje, sredstva za otpornost na udarce, usporivači HR P20150482 T1 gorenja, antistatička sredstva, umreživači, fluorescentna bjelila, toplinski vodiči, električni vodiči, sredstva za kontrolu prodiranja, magnetska sredstva, surfaktanti, stabilizatori, pomoćne tvari, lijekovi, otapala, učvršćivači, sredstva za upijanje vlage, sredstva za ojačavanje, arome, antimikrobna sredstva i njihove smjese.
the valine at position 2 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, F, I, L, M, Q, T, W, and Y; 
(i) valin na položaju 2 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine kojučne A, C,F,1,L,M,Q,T, W te Y;
is selected from the group consisting of alkoxy, alkylthio, optionally substituted aryl, heteroaryl, and heterocyclyl groups, and optionally protected amino, hydroxy, and guanidino groups; and 
R* je izabran iz grupe koju čine alkoksi, alkiltio, izborno supstituirani aril, heteroaril i heterociklil grupe, i izborno zaštićene amino, hidroksi i guanidino grupe; i
18.6 g of solids were recovered. 
18.6 g krutine je izdvojeno.
The composition of claim 19 for use in the treatment of cancer or neoplasticity, further comprising a bispecific ligand, said bispecific ligand comprising a first arm that carries specificity for a minicell surface structure and a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor. 
Pripravak prema zahtjevu 19 za uporabu u liječenju raka ili neoplastičnog poremećaja, dalje sadrži bispecifični ligand, taj bispecifični ligand ima prvi krak koji nosi specifičnost za strukturu površine mini-stanice i drugi krak koji nosi specifičnost za ne-fagocitni receptor površine stanice sisavca.
The compound of claim 10, wherein the disorder or disease is selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Uporaba prema patentnom zahtjevu 10, naznačena time što je poremećaj 1li bolest izabran/izabrana iz grupe koju čine poremećaji i bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji 1 bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
Process according to any of claims 1 to 15, characterised in that said hydrophobically modified polyalkyleneimine is added in an amount of from 5 to 50 mg of said hydrophobically modified polyalkyleneimine/m2, preferably of from 10 to 45 mg of said hydrophobically modified polyalkyleneimine/m2 of silicate in said mineral material of step a). 
Proces prema bilo kojem od zahtjeva 1 do 15, naznačen time što se hidrofobno modificirani polialkilenimin dodaje u količini od 5 do 50 mg tog hidrofobno modificiranog polialkilenimina/m', poželjno od 10 do 45 mg tog hidrofobno modificiranog polialkilenimina/m? silikata u mineralnom materijalu iz koraka a).
The method of paragraph 28 or 29, wherein steps (a) and (b) are performed sequentially, with step (a) performed prior to step (b). 
Postupak prema zahtjevu 24 ili 25, naznačen time da se koraci (a) i (b) provode uzastopno, s korakom (a) provedenim prije koraka (b).
the preparation a has at least 1% of glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines, or chemically modified glycosaminoglycan, hydrolyzed glycosaminoglycans, glycosamines with cyclic polycarbonates or with Pre-polymer of polyhydroxyurethanes terminated by cyclic carbonates functions (PRE-CC) or a blend of those different constituents in a blend containing acceptable solvents and optionally CC monomers of PHU or PRE-CC or a blend of PRE-CC and CC to ensure that the preparation a contains cyclic carbonate functions, and 
pripravak a ima barem 1 % glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina ili kemijski modificiranih glikozaminoglikana, hidroliziranih glikozaminoglikana, glikozamina s cikličkim polikarbonatima ili s Pre-polimerom polihidroksiuretana terminiranog funkcijama cikličkih karbonata (PRE-CC) ili mješavinu spomenutih različitih sastojaka u mješavini koja sadrži prihvatljiva otapala i izborno CC monomere od PHU ili PRE-CC ili mješavinu PRE-CC i CC kako bi se osiguralo da pripravak a sadrži funkcije cikličkih karbonata, i
Nicotine-containing granulate according to one of claims 1 to 4, characterized in that the pharmaceutically acceptable nicotine derivative is a solid nicotine derivative, in particular is a solid nicotine derivative selected from the group consisting of nicotine bitartrate, nicotine polacrilin, nicotine betadex, nicotine polacrilex, and combinations thereof. 
Postupak dobivanja granulata koji sadrži nikotin u skladu s patentnim zahtjevom 4 ili 5, naznačen time što je farmaceutski prihvatljiva nikotinska sol ili kompleks upotrijebljeni u koraku (a) čvrsta nikotinska sol ili kompleks, a osobito čvrsta nikotinska sol ili kompleks koje se bira iz skupine koju čine nikotin-bitartarat, nikotin-polakrilin, nikotin-betadeks, nikotin-polakrileks, te njihove kombinacije.
Zirconia in the metastable tetragonal phase (specific volume=0.16 cm3/g) which can transform into the monoclinic phase (specific volume=0.17 cm3/g) (volume ratio=1.045); 
Cirkonijev oksid u metastabilnoj tetragonskoj fazi (specifični volumen = 0.16 cm?/g) koja se može transformirati u monoklinsku fazu (specifični volumen = 0.17 cm*/g) (volumni omjer = 1.045);
The composition according to claim 6, wherein at least 95% by weight of said solid N-benzoyl-staurosporine is the crystalline form II according to claim 1 . 
Spoj prema zahtjevu 5, naznačen time, da pri čemu je najmanje 95 masenih % od spomenute krutine N-benzoil-staurosporina u kristalnom obliku II.
(b4) an antibody H chain consisting of the amino acid sequence having at least 70% sequence identity with amino acid sequence of SEQ ID NO: 7; 
(b4) H-lanac protutijela koji se sastoji od aminokiselinske sekvence SEQ ID NO: 7;
An isolated peptide being 10 amino acids in length, having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-4 and 55, the peptide being capable of inhibiting alpha synuclein aggregation. 
Jedan izolirani dugi peptid, sa sekvencom aminokiselina odabranom iz skupine koja se sastoji iz SEQ ID br. 1-4 i 55, naznačen time da je peptid prikladan za inhibiciju alfa sinuklein agregacije.
A sensor assembly according to claim 1, wherein said first coated optical fiber is in contact with both of said first and second rigid transverse-load-applying structures along a contact zone having first and second ends spaced from one another along said length, wherein said first Bragg grating is distal from each of said first and second ends. An electrical transformer, comprising: 
Senzoričko sklopovlje u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačeno time što je navedeno prvo obloženo optičko vlakno u kontaktu s obje od navedene prve i druge čvrste strukture koje primijenjuju poprečno opterećenje duž zone kontakta čiji su prvi i drugi krajevi međusobno razmaknuti duž navedene duljine, gdje je navedena prva Braggova rešetka udaljena od svakog od navedenog prvog i drugog kraja.
For most Meldonium salts, their pharmacokinetic properties practically do not differ from those described for Meldonium. 
Za većinu soli meldonija, njihova farmakokinetička svojstva se praktički ne razlikuju od onih koja su opisana za meldonij.
The composition of claim 1 or the composition for the use according to claim 2, wherein 100 % of said M. tb are inactivated. 
Pripravak u skladu s patentnim zahtjevom 1 ili pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 2, naznačen time što se inaktivira 100% od navedenih stanica M. tb.
The combination as defined in claim 4 wherein the antidiabetic agent is at least one agent selected from the group consisting of a biguanide, a sulfonyl urea, a glucosidase inhibitor, a PPAR gamma agonist, a PPAR alpha/gamma dual agonist, an aP2 inhibitor, a DPP4 inhibitor, an insulin sensitizer, a glucagon-like peptide-1 (GLP-1), a PTP1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, insulin and a meglitinide. 
Kombinacija prema patentnom zahtjevu 4, naznačena time što je antidijabetično sredstvo najmanje jedno sredstvo izabrano iz grupe koju čine biguanid, sulfonil urea, inhibitor glukozidaze, PPAR gama agonist, PPAR alfa/gama dvostruki agonist, aP2 inhibitor, DPP4 inhibitor, sredstvo koje povećava osjetljivost na inzulin, glukagonu-sličan peptid-1 (GLP-I), PTPIB inhibitor, inhibitor glikogen fosforilaze, inhibitor glukozo-6-fosfataze, inzulin 1 meglitinid.
iii) the second Fab fragment, the third Fab fragment and the Fc domain are part of an immunoglobulin molecule and the immunoglobulin molecule is an IgG1 or IgG4 subclass immunoglobulin molecule; and/or iv) the second Fab fragment, the third Fab fragment and the Fc domain are part of an immunoglobulin molecule and the immunoglobulin molecule is a human immunoglobulin molecule. 
iii) drugi Fab fragment, treći Fab fragment i Fc domena su dio molekule imunoglobulina, a molekula imunoglobulina je molekula imunoglobulina podrazreda IgG1 ili IgG4; i/ili iv) drugi Fab fragment, treći Fab fragment i Fc domena su dio molekule imunoglobulina, a molekula imunoglobulina je molekula humanog imunoglobulina.
each independently represents an unsubstituted or substituted C1-8 alkyl group, an unsubstituted C2-8 alkenyl group, an unsubstituted C2-8 alkynyl group, an unsubstituted C3-8 cycloalkyl group, an unsubstituted or substituted hydroxyl group, a halogeno group, a cyano group, or a nitro group; 
R* predstavlja skupinu C1s alkil, skupinu Cis4 haloalkil, skupinu C5.1o aril C,g4 alkil, skupinu C3.g cikloalkil, skupinu C4.19 aril, skupinu C,.; acil, skupinu C1.4 alkoksikarbonil, skupinu C1.4 alkoksi, amino skupinu, skupinu
A genic expression adenoviral hybrid vector according to claim 12, wherein the exogenous gene of interest is a therapeutic gene selected from the colony stimulating factor (GMCSF), alpha-interferon and herpes simplex virus thymidine kinase (HSV-TK) genes. 
Adenovirusni hibridni vektor sa genskom ekspresijom prema patentnom zahtjevu 12, naznačen time što jo egzogeni gen od interesa terapeutski gen izabran od gena za faktor stimulacije kolonije (GMCSF), alfa-interferon i timidin kinazu herpes simplex virusa (HSV-TK).
If an increase in dosage is required, then the dosage may be increased at an appropriate interval, e.g., every three to seven days. 
Ako je potrebno povećanje doziranja, tada se doziranje može povećati u odgovarajućem intervalu, npr. svaka tri do sedam dana.
The progenitor cell population according to claim 1, wherein the cell population is capable of migrating to a specific, damaged tissue in a patient. 
Progenitorna stanica prema zahtjevu 1, naznačena time, što: stanica posjeduje sposobnost migracije do specifičnog, oštećenog tkiva bolesnika;
A nucleic acid molecule according to claim 6, wherein said nucleic acid molecule is operably linked to a control sequence. 
Molekula nukleinske kiseline, pri čemu navedena molekula nukleinske kiseline kodira protein koji veže antigen iz bilo kojeg od prethodnih patentnih zahtjeva, navedena molekula nukleinske kiseline je operabilno povezana s kontrolnim slijedom.
A construction according to any one of the preceding claims wherein between the first and second concave surfaces there is one or more frusto-conical or cylindrical connecting formations. 
Konstrukcija kotača u skladu s patentnim zahtjevom 1, naznačena time da se između primarnih i sekundarnih konkavnih površina (41, 42) nalazi jedna ili više spojnih formacija u obliku krnjeg stošca ili cilindra.
Method according to one of the claims 23 to 30 or use according to one of the claims 31 to 33 wherein the patient is an individual who shows one, two or more of the following conditions: 
Farmaceutski sastav za uporabu prema zahtjevu 9, naznačen time, da je pacijent pojedinac kod kojega se pokazuje jedno, dva ili više sljedećih stanja:
System according to claim 12 or 13, wherein the drill-pulling device is arranged at a starting point of the shank to be drilled out and the pipeline pressure device is arranged at an end point of the shank to be drilled out. 
Sustav, prema zahtjevima 12. ili 13., naznačen time da je uređaj (15) za povlačenje bušilice postavljen na početnu točku provrta (10) kojega treba izbušiti i da je cjevovodni tlačni uređaj (1) postavljen na krajnju točku provrta (10) kojega treba izbušiti.
The method of claim 13, wherein the compound is administered orally. 
ili time što je spoj izabran od spoja formule (I-B):
wherein following oral administration the unit dosage form, is more than 50% dissolved in the stomach prior to being released into the small intestines. 
Jedinični dozirni oblik prema zahtjevu 6, gdje se nakon oralne primjene jediničnog dozirnog oblika više od 50% otapa u želucu prije oslobađanja u tanko crijevo.
Different materials may be selected for the shell or cup wherein also at least one of those may be made of a plastic material. 
Za izradu ljuske ili čaše mogući su razni materijali, a jedna od ovih može biti načinjena također i od odgovarajućeg plastičnog materijala.
a light chain variable region comprising: a first CDR comprising SEQ ID NO:6; 
varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10.
The composition according to claim 5, wherein the anti-HCV agent is an inhibitor of HCV polymerase. 
Sastav prema zahtjevu 15, naznačen time, da sljedeće anti-HCV-sredstvo je dodatni inhibitor HCV-polimeraze.
0.01-0.6 % by weight of micronised corticosteroid, preferably micronised fluticasone propionate; 
0,01-0,6%, težinski, mikroniziranog flutikazon-propionata, ili njegove farmaceutski prihvatljive soli ili derivata;
is selected from the group consisting of chloro and trifluoromethyl; 
R* je izabran iz grupe koja se sastoji od izopropenil.
wherein 30% by weight of the cannabinoid is released within 5 minutes after ingestion, based on the total weight content of the cannabinoid in the chewing gum composition, and wherein the release starts within 3 minutes after ingestion. The chewing gum composition according to claim 1, wherein the cannabinoids comprise tetrahydrocannabinol (THC). 
Pripravak u obliku žvakaće gume u skladu s patentnim zahtjevom 1, naznačen time što pripravak za žvakanje sadrži 0,01 do 15 %, težinski, kanabinoida, na osnovi ukupne težine pripravka u obliku žvakaće gume.
The method according to claim 9, wherein the compound of formula I is provided in the form of the hydrochloride salt. 
Spoj za upotrebu prema zahtjevu 8, naznačen time što je spoj s formulom I osiguran u obliku hidrokloridne soli.
a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:129 and a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:128; 
VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 129 i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 128;
A pharmaceutical composition comprising the compound of any of claims 1 to 14 and a suitable excipient. 
Farmaceutski sastav koji sadrži spoj patentnog zahtjeva 1 i odgovarajući ekscipijens.
To this reaction mixture was added DMF (29.56 mL, 0.383 mol) and the resulting mixture was stirred for an additional 1 h at −78° C. The reaction mixture turned black-blue after the addition of DMF. 
Toj se reakcijskoj smjesi doda DMF (29,56 mL; 0,383 mol), te se nastala smjesa miješa dodatnih 1 h pri temperaturi od -78 *C. Dodatkom DMF reakcijska smjesa postane plavo-crna.
and R2 are both —OR8, or R1 and R2, together with the carbon atom to which they are attached, form dioxacycloalkyl; 
(i) R'iR su oba -ORÅ *, ili R' i R", zajedno s atomom ugljika na kojeg su vezani, tvore dioksacikloalkil;
A humanised antibody comprising the variable light chain (VL) of SEQ ID NO:4 and the variable heavy chain (VH) of SEQ ID NO:9, wherein the antibody does not comprise fucose on the core carbohydrate structure attached to Asn297. 
Humanizirano protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što humanizirano protutijelo ne sadrži fukozu na osnovnoj ugljikohidratnoj strukturi vezanoj na Asn297.
The compound of claim 18, wherein Rc5 is a leaving group selected from the group consisting of a halogen, p-toluenesulfonyloxy, methanesulfonyloxy, and trifluoromethanesulfonyloxy. 
Spoj u skladu s patentnim zahtjevom 18, naznačen time što je R* izlazna skupina koju se bira iz skupine koju čine halogen, p-toluensulfoniloksi, metansulfoniloksi i trifluormetansulfoniloksi.
Use according to claim 12 or 13, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, dysembryoplastic neuroepithelial tumor, oligodendrogliomas, ependymoma, glioblastoma multiforme, mixed gliomas, oligoastrocytomas, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, teratoma, gangliogliomas, gangliocytoma, central gangliocytoma, primitive neuroectodermal tumors (PNET, e.g. medulloblastoma, medulloepithelioma, neuroblastoma, retinoblastoma, ependymoblastoma), tumors of the pineal parenchyma (e.g. pineocytoma, pineoblastoma), ependymal cell tumors, choroid plexus tumors, neuroepithelial tumors of uncertain origin (e.g. gliomatosis cerebri, astroblastoma) or glioblastoma, lung cancer or adenosquamous carcinoma. 
Cjepivo u skladu s patentnim zahtjevom 10 za upotrebu u skladu s patentnim zahtjevom 10, pri čemu je navedeni karcinom neki od sljedećih: astrocitom, pilocitični astrocitom, disembrioplastičan neuroepitelijalni tumor, oligodendrogliomi, ependimomi, glioblastom multiforme, miješani gliomi, oligoastrocitomi, meduloblastomi, retinoblastomi, neuroblastom, germinom, teratom, gangliogliomi, gangliocitom, centralni gangliocitom, primitivni neuroektodermalni tumori (PNET), meduloblastom, meduloepiteliom, neuroblastom, retinoblastom, ependimoblastom, tumori pinealno parenhima, pineocitom, pineoblastom, tumorni ependimalnih stanica, tumori koroidnog pleksusa, neuroepitelijalni tumori nepoznatog podrijetla, gliomatosis cerebri, astroblastom i glioblastom.
The image processing apparatus according to any of claims 1 to 3, wherein the image processing apparatus performs image processing so as the isotropic blur image and the anisotropic blur image to be subtracted less largely from the band image as the edge reliability corresponding to the pixel to be processed becomes lower. 
Uređaj za obradu slike prema bilo kojem od zahtjeva 1 do 3, naznačen time, da uređaj za obradu slike izvodi obrađivanje slike tako, što se izotropna zamagljena slika (P1) i neizotropna zamagljena slika (P2) trebaju odbiti iz slike na traci (a, fB, y) manje opsežno, kako pouzdanost rubova (E) odgovarajuća za piksel koji se treba obraditi, postaje manja.
The prodrug of claim 8, wherein the backbone moieties comprise a structure of the following formula: wherein n is an integer of from 5 to 50 and the dashed line indicates attachment to the rest of the molecule. 
Predlijek prema patentnom zahtjevu 6, naznačen time što dijelovi okosnice sadrže strukturu sljedeće formule: pri čemu n je cijeli broj od 5 do 50 i isprekidana crta označava vezanje na ostatak molekule.
Use of 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrrimidin-4-one or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of multiple system atrophy (MSA). 
Uporaba 1-(2-izopropoksietil)-2-tiokso-1,2,3,5-tetrahidro-pirolo[3,2-d]pirimidin-4-ona ili njegove farmaceutski prihvatljive soli naznačena time da je za proizvodnju lijeka za liječenje multiple sistemske atrofije (MSA).
The Wave-generating apparatus (1), according to claim 5, wherein the profile (5) is inflated with air. 
Uređaj za generiranje valova (1), sukladno zahtjevu 5, pri čemu je profil (5) napunjen zrakom.